Joel Sorger

Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children's Oncology Group trials

Sapna Oberoi, Wei Xue, Amira Qumseya, Thomas J. Scharschmidt et autres

BACKGROUND: Long-term survival and prognostic factors for patients with extremity rhabdomyosarcoma (RMS) treated on contemporary Children's Oncology Group (COG) trials are unknown. METHODS: Data of extremity RMS patients enrolled on COG trials from 1998 to 2014 were analyzed to estimate event-free survival …

ca, us (code pays fourni par la source)

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)

Theodore W. Laetsch, Stephan D. Voss, Kathleen Ludwig, David Hall et autres

PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of …

us (code pays fourni par la source)

Outcome of children and young adults with localized extremity rhabdomyosarcoma treated on Children's Oncology Group trials.

Sapna Oberoi, Wei Xue, Amira Qumseya, Thomas J. Scharschmidt et autres

10006 Background: Extremity rhabdomyosarcoma (RMS) accounts for 15-20% of patients with localized RMS. The long-term survival and associated prognostic factors of extremity RMS patients treated on the contemporary Children’s Oncology Group (COG) trials have not been reported. Methods: Patients with localized extremity …

ca, us (code pays fourni par la source)

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

Theodore W. Laetsch, Kathleen Ludwig, David Hall, Donald A. Barkauskas et autres

10008 Background: NTRK1/2/3 gene fusions (TRK fusions) occur in a range of pediatric cancers and are the canonical molecular alterations in IFS. Larotrectinib is a highly selective TRK inhibitor that is FDA-approved for TRK fusion solid tumors in patients with no satisfactory …

us (code pays fourni par la source)

ASO Visual Abstract: Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy—A New Standard of Care?

Jo Cooke‐Barber, Joseph G. Brungardt, Michael Sorger, Joseph G. Pressey et autres

us (code pays fourni par la source)

ASO Author Reflections: Minimizing Time in Hospital via Bone Biopsy or Other Means

Jo Cooke‐Barber, Joseph G. Brungardt, Michael Sorger, Joseph G. Pressey et autres

us (code pays fourni par la source)

Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology

Mark L. Kayton, Aaron R. Weiss, Wei Xue, Odion Binitie et autres

BACKGROUND AND OBJECTIVES: The impact upon wound healing of targeted molecular therapies, when incorporated into neoadjuvant therapy of soft tissue sarcoma, is largely unknown. Here, we describe wound complications following addition of pazopanib, a tyrosine kinase inhibitor (TKI), to neoadjuvant radiotherapy (RT) …

us (code pays fourni par la source)

Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy—A New Standard of Care?

Jo Cooke‐Barber, Joseph G. Brungardt, Michael Sorger, Joseph G. Pressey et autres

us (code pays fourni par la source)

Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors

Michelle Ghert, Patricia Schneider, Victoria Giglio, Andrew Duong et autres

IMPORTANCE: The use of perioperative, prophylactic, intravenous antibiotics is standard practice to reduce the risk of surgical site infection after oncologic resection and complex endoprosthetic reconstruction for lower extremity bone tumors. However, evidence guiding the duration of prophylactic treatment remains limited. OBJECTIVE: …

ca, es, us (code pays fourni par la source)

Novel ARHGAP23‐FER fusion in a metastatic spindle cell–predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib

Alina Sadaf, Sara Szabo, Katelyn Ferguson, Joel Sorger et autres

A metastatic spindle‐cell soft‐tissue neoplasm was found to carry a novel ARHGAP23‐FER fusion. The tumor showed a rapid and sustained metabolic response to tyrosine kinase inhibitor lorlatinib.

us (code pays fourni par la source)

Implant Survival and Clinical Outcomes of Total Hip Arthroplasty in Adolescent and Young Adult Patients

Lauren Zeitlinger, Anthony Gemayel, Patrick W. Whitlock, Joel Sorger

Abstract Total hip arthroplasty (THA) in pediatric patients is controversial with concern for high failure rates, and lack of promising outcomes as compared with the adult population. Increased survivorship of implants invites the potential for improved function and quality of life in …

us (code pays fourni par la source)

A large intermuscular shoulder lipoma causing pain and weakness in an 87-year-old patient: a case report

Samer S. Hasan, Jack P. O’Loughlin, Joel Sorger

Rotator cuff dysfunction is more common with advancing age; the prevalence of full-thickness rotator cuff tears has been estimated at 22% in patients older than 65 years3 and 51% in patients older than 80 years,19 although many of these arise insidiously and …

us (code pays fourni par la source)